서울대학교 생물정보연구소와 생물정보학 협동과정 공동 주최로 특별 세미나를 아래와 같이 열고자 하오니,　많은 참여 바랍니다.

일시: 2015년　4월　16일 목요일 오전　11시

연사:　고 영 일 교수님　(서울대학교 병원 종양내과)

장소:　서울대학교　25-1동　103호

TITLE

Cancer genome research at ICGC (International Cancer Genome Consortium)

ABSTRACT

International Cancer Genome Consortium (ICGC) is a global consortium focusing on cancer genomics. It has a mission of generating comprehensive catalogues of genomic abnormalities in tumors from 50 different cancer types. The Cancer Genome Atlas (TCGA) is one of major collaborator in ICGC. Korean research groups are participating in ICGC with acute myeloid leukemia, non-small cell lung cancer, and breast cancer.

Various types of next generation sequencing data–　i.e. whole genome sequencing (WGS), whole exome sequencing (WES), whole transcriptome sequencing (WTS) - of more than 2000 patients are collected in ICGC so far. Using these data, ICGC has a pan-cancer analysis working group (PCWAG) project which analyze these data altogether to answer specific scientific questions. These questions include diverse topic such as “evolution and heterogeneity”, “Mitochondrial DNA”, and “Mutations in regulatory regions”.

Brief overview of ICGC PCAWG projects and participation of Korean researchers would be discussed during my talk.

CAREER

2014.3　–　Assistant professor, Hematology/Medical Oncology, SNUH, Seoul, Korea

2013.5 - 2014.2 Clinical Fellow in Hematology/Medical Oncology, SNUH, Seoul, Korea

2010.3 - 2013.4 Public Service Doctor, Kkotdongnae, Gapyeong, Korea (Military service)

2010.2, Board Certified in Internal Medicine, SNUH, Seoul, Korea

2005.2, MD, Seoul National University College of Medicine, Seoul, Korea

EDUCATION

2010.3 - PhD. Candidate, Molecular and Clinical Oncology, Seoul National University, Seoul, Korea

2010.2, Masters in Molecular and Clinical Oncology, Seoul National University, Seoul, Korea

2005.2, Medical Doctor’s Degree, Seoul National University, Seoul, Korea

AWARDS

1997 Silver medal, 38thInternationalMathematicsOlympiad,Argentina

1998 Bronze medal, 39thInternationalMathematicsOlympiad,Taiwan

2008 Best doctor for patients, Seoul National University Hospital

2008 Travel Award, American Society of Hematology Annual Meeting

2011 Best Oral Presentation Award, Korea Cancer Association Annaul Meeting

2012 Best Oral Presentation Award, Korean Association for Clinical Oncology Annual Meeting

TRIALS

A Phase 3 Randomized Study of the Efficacy and Safety of Posaconazole versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults

A Phase 3, Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physician's Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)

PUBLICATION (1stauthoronly,includingco-firstauthor)

1.　Koh Y, Lee HE, Im SA, et al. VEGF expression is related to good response and long progression-free survival in gastrointestinal stromal tumor patients treated with Sunitinib. Diagnostic molecular pathology : the American journal of surgical pathology, part B 2011;20:143-7.

2.　Kim I, Koh Y, Yoon SS, et al. Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patients. American journal of hematology 2013;88:10-5.

3.　Park S, Koh Y, Jung SH, Chung YJ. Application of array comparative genomic hybridization in chronic myeloid leukemia. Methods in molecular biology 2013;973:55-68.

4.　Koh Y, Lim HY, Ahn JH, et al. Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013;24:1026-31.

5.　Koh Y, Kim I, Shin DY, et al. Polymorphisms in genes that regulate cyclosporine metabolism affect cyclosporine blood levels and clinical outcomes in patients who receive allogeneic hematopoietic stem cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2012;18:37-43.

6.　Koh Y, Lee HE, Oh DY, et al. The lack of CD34 expression in gastrointestinal stromal tumors is related to cystic degeneration following imatinib use. Japanese journal of clinical oncology 2012;42:1020-7.

7.　Koh Y, Kim DW, Kim TM, et al. Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011;6:905-12.

8.　Koh Y, Jang B, Jeon YK, et al. EGFR gene copy number gain is related to high tumor SUV and frequent relapse after adjuvant chemotherapy in resected lung adenocarcinoma. Japanese journal of clinical oncology 2011;41:548-54.

9.　Koh Y, Kim DY, Park SH, et al. GSTT1 copy number gain is a poor predictive marker for escalated-dose imatinib treatment in chronic myeloid leukemia: genetic predictive marker found using array comparative genomic hybridization. Cancer genetics and cytogenetics 2010;203:215-21.

10.　Koh Y, Kim I, Bae JY, et al. Prognosis of secondary acute myeloid leukemia is affected by the type of the preceding hematologic disorders and the presence of trisomy 8. Japanese journal of clinical oncology 2010;40:1037-45.

11.　Koh Y, Lee HR, Song EY, et al. Hypoplastic myelodysplastic syndrome (h-MDS) is a distinctive clinical entity with poorer prognosis and frequent karyotypic and FISH abnormalities compared to aplastic anemia (AA). Leukemia research 2010;34:1344-50.

12.　Koh Y, Kim I, Yoon SS, et al. Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib. Annals of hematology 2010;89:725-31.

13.　Koh Y, Jang B, Han SW, et al. Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010;5:320-5.

14.　Koh Y, Bang SM, Lee JH, et al. Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide. Annals of hematology 2010;89:201-6.

15.　Koh Y, Kim TM, Jeon YK, et al. Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20:1414-9.

16.　Koh Y, Park J, Ahn KS, et al. Different clinical importance of FLT3 internal tandem duplications in AML according to FAB classification: possible existence of distinct leukemogenesis involving monocyte differentiation pathway. Annals of hematology 2009;88:1089-97.

17.　Koh Y, Park J, Bae EK, et al. Non-A type nucleophosmin 1 gene mutation predicts poor clinical outcome in de novo adult acute myeloid leukemia: differential clinical importance of NPM1 mutation according to subtype. International journal of hematology 2009;90:1-5.

18.　Koh Y, Jung WJ, Ahn KS, Yoon SS. Establishment of cell lines from both myeloma bone marrow and plasmacytoma: SNU_MM1393_BM and SNU_MM1393_SC from a single patient. BioMed research international 2014;2014:510408.

19.　Koh Y, Lee SY, Kim I, et al. Bortezomib-associated peripheral neuropathy requiring medical treatment is decreased by administering the medication by subcutaneous injection in Korean multiple myeloma patients. Cancer chemotherapy and pharmacology 2014;74:653-7.